Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy.
BACKGROUND
Plasminogen activators (PA) may be released by the gut and eliminated by the liver. Patients with liver disorders or malignancy often have abnormal plasma levels of PAs. Some tumours may produce PAs.


METHODS
In patients undergoing gastric surgery for malignant (n = 18) or benign (n = 21) disorders., blood drawn from the portal vein and a peripheral vein was analysed for tissue-type plasminogen activator antigen and activity (tPA: Ag, tPA: Act), single-chain urokinase-type plasminogen activator activity (scuPA: Act), and plasminogen activator inhibitor antigen and activity (PAI: Ag, PAI: Act).


CONCLUSIONS
In both groups tPA: Act and scuPA: Act levels were significantly higher in portal blood than in peripheral blood, but tPA: Ag and PAI: Act levels did not differ. PAI: Act levels were significantly lower in patients with malignant disease, but levels of the other markers did not differ in the two groups.
Rahr
H B
HB
Venous Thrombosis Group, Aalborg Hospital, Denmark.
Sørensen
J V
JV
Larsen
J F
JF
Jensen
F S
FS
Bredahl
C
C
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000032:analysis*; D015849:Plasminogen Inactivators / Q000032:analysis*; D011169:Portal Vein; D012016:Reference Values; D013274:Stomach Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery
D014408:Biomarkers, Tumor; D015849:Plasminogen Inactivators; D010960:Plasminogen Activators